A PYMNTS Company

US/UK: Pfizer, AstraZeneca merger bites the dust

By  |  May 27, 2014

Just days after UK pharmaceutical firm AstraZeneca rejected a $119 billion acquisition bid, Pfizer says it will no longer pursue the acquisition, ending the chances of a new top industry player of emerging.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Pfizer announced Monday it would no longer pursue AstraZeneca and would not consider a hostile takeover bid. Under UK competition rules, according to reports, Pfizer cannot submit another bid for the company for six months.

    The US pharmaceutical firm’s news came on the last possible day for it to decide whether it would pursue another acquisition attempt or not.

    Full content: DealBook

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.